RE:RE:RE:RE:TLT 2022skys1 wrote: I don't think things are going too well for the cancer drugs like Keytruda, Opdivo, Infinzi etc. Check out the latest stories and headlines of drug makers pulling their products of the shelves, due to lack of results plus flubed trials. "Merck's Keytruda misses mark in small cell lung cancer trial, dasking big expansion hopes". or Bristiol Meyers pulling Opivo because of a liver trial failure, same for AstraZeneca and Infinzi.
Plus IMO, Keytruda just hasn't been that effective, but there really isn't anything else other than Chemo and it's terrible side effects.
Yeah Skys,
I have no idea how many patients will ultimately be treated in TLT's Phase 2? If it is more than 50 then I think the CR%s could be pretty huge. One of the above pharmas will want this tech. Both for NMIBC and many other indications. Hopefully TLT can arrange the bidding war that should ensue. I think sometime in 2022 the CR numbers will be in for at least 90day data on that 50 or so patients? It could be in the high 80s or low 90s %.
Maybe it is time to trademark Optivolase, Infinzilase, and Keytrudalase? Lol